IGFBP2 and metabolic dysfunction-associated steatotic liver disease: In patients with MASLD, the serum IGFBP2 level showed an inverse correlation with CAP values (r = −0.133, P < 0.05) and was identified as an independent determinant of hepatic steatosis (β = −0.104, P < 0.05), while no significant association was observed between LSM and IGFBP2 (P > 0.05).